European Journal of Cancer
Volume 46, Issue 9 , Pages 1632-1639 , June 2010

Mortality is persistently increased in Hodgkin’s lymphoma survivors

  • Cecilie E. Kiserud

      Affiliations

    • National Resource Center for Late Effects, Department of Oncology, Oslo University Hospital and University of Oslo, Norway
    • Corresponding Author InformationCorresponding author: National Resource Center for Late Effects, Department of Oncology, Oslo University Hospital (The Norwegian Radium Hospital), 0310 Oslo, Norway. Tel.: +47 22934000; fax: +47 22 93 45 53.
    • ,
  • Jon Håvard Loge

      Affiliations

    • National Resource Center for Late Effects, Department of Oncology, Oslo University Hospital and Department of Behavioral Sciences in Medicine, University of Oslo, Norway
    • ,
  • Alexander Fosså

      Affiliations

    • Department of Oncology, Oslo University Hospital, Norway
    • ,
  • Harald Holte

      Affiliations

    • Department of Oncology, Oslo University Hospital, Norway
    • ,
  • Milada Cvancarova

      Affiliations

    • National Resource Center for Late Effects, Department of Oncology, Oslo University Hospital and University of Oslo, Norway
    • ,
  • Sophie D. Fosså

      Affiliations

    • National Resource Center for Late Effects, Department of Oncology, Oslo University Hospital and University of Oslo, Norway

Received 22 November 2009 ,Revised 4 February 2010 ,Accepted 8 February 2010.

References 

  1. Abrahamsen AF, Loge JH, Hannisdal E, et al. Late medical sequelae after therapy for supradiaphragmatic Hodgkin’s disease. Acta Oncol. 1999;38(4):511–515
  2. Aleman BM, van den Belt-Dusebout AW, et al. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol. 2003;21(18):3431–3439
  3. Aleman BMP, van den Belt-Dusebout A, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109(5):1878–1886
  4. Behringer K, Breuer K, Reineke T, et al. Secondary amenorrhea after Hodgkin’s lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2005;23(30):7555–7564
  5. Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin’s lymphoma. J Clin Oncol. 2007;25(12):1489–1497
  6. Howell SJ, Radford JA, Ryder WD, Shalet SM. Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiency. J Clin Oncol. 1999;17(5):1493–1498
  7. Howell SJ, Radford JA, Adams JE, Shalet SM. The impact of mild Leydig cell dysfunction following cytotoxic chemotherapy on bone mineral density (BMD) and body composition. Clin Endocrinol. 2000;52:609–616
  8. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290(21):2831–2837
  9. Viviani S, Santoro A, Ragni G, et al. Gonadal toxicity after combination chemotherapy for Hodgkin’s disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol. 1985;21(5):601–605
  10. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol. 2002;20(8):2101–2108
  11. Provencio M, Millan I, Espana P, et al. Analysis of competing risks of causes of death and their variation over different time periods in Hodgkin’s disease. Clin Cancer Res. 2008;14(16):5300–5305
  12. Favier O, Heutte N, Stamatoullas-Bastard A, et al. Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer. 2009;
  13. Mols F, Vingerhoets AJ, Coebergh JW, et al. Better quality of life among 10–15 year survivors of Hodgkin’s lymphoma compared to 5–9 year survivors: a population-based study. Eur J Cancer. 2006;42(16):2794–2801
  14. Wettergren L, Bjorkholm M, Axdorph U, Langius-Eklof A. Determinants of health-related quality of life in long-term survivors of Hodgkin’s lymphoma. Qual Life Res. 2004;13(8):1369–1379
  15. Kornblith AB, Herndon JE, Zuckerman E, et al. Comparison of psychosocial adaptation of advanced stage Hodgkin’s disease and acute leukemia survivors. Cancer and Leukemia Group B. Ann Oncol. 1998;9(3):297–306
  16. Ruffer JU, Flechtner H, Tralls P, et al. Fatigue in long-term survivors of Hodgkin’s lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer. 2003;39(15):2179–2186
  17. Abrahamsen AF, Loge JH, Hannisdal E, Holte H, Kvaloy S. Socio-medical situation for long-term survivors of Hodgkin’s disease: a survey of 459 patients treated at one institution. Eur J Cancer. 1998;34(12):1865–1870
  18. Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S. Hodgkin’s disease survivors more fatigued than the general population. J Clin Oncol. 1999;17(1):253–261
  19. Abrahamsen AF, Egeland T, Hansen S, et al. Hodgkin’s disease in a national and hospital population: trends over 20 years. Eur J Cancer. 1997;33(14):2380–2383
  20. Holte H, Mella O, Wist E, et al. ChlVPP is as effective as alternating ChlVPP/ABOD in advanced stage Hodgkin’s disease. Acta Oncol. 1996;35(Suppl. 80):
  21. Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. J Psychosom Res. 1993;37:147–153
  22. Pintilie M. Competing risks: a practical perspective. Wiley; 2006;
  23. Raboud J, Breslow NE. Efficiency gains from the addition of controls to matched sets in cohort studies. Stat Med. 1989;8(8):977–985
  24. Barchielli A, Balzi D. Nine-year follow-up of a survey on smoking habits in Florence (Italy): higher mortality among non-responders. Int J Epidemiol. 2002;31(5):1038–1042
  25. Heilbrun LK, Nomura Abra, Stemmermann GN. The effects of non-response in a prospective study of cancer: 15-year follow-up. Int J Epidemiol. 1991;20(2):328–338
  26. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009;

PII: S0959-8049(10)00113-9

doi: 10.1016/j.ejca.2010.02.010

European Journal of Cancer
Volume 46, Issue 9 , Pages 1632-1639 , June 2010

Article Tools

* Image Usage & Resolution